<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03724409</url>
  </required_header>
  <id_info>
    <org_study_id>201805910</org_study_id>
    <secondary_id>P50CA174521</secondary_id>
    <nct_id>NCT03724409</nct_id>
  </id_info>
  <brief_title>Selective Intra-arterial Injection of PRRT in Neuroendocrine Tumor Patients With Liver Metastases</brief_title>
  <official_title>Selective Intra-arterial Injection of Peptide Receptor Radionuclide Therapy (PRRT) in Neuroendocrine Tumor Patients With Liver Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sandeep Laroia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Holden Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Iowa</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a safety study to determine the phase 1 starting dose of [90]Yttrium-DOTATOC when it
      is administered intravenously for patients with neuroendocrine tumors that have spread to the
      liver.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      [90]Yttrium-DOTATOC is a radioactive drug used for peptide receptor radionuclide therapy
      (PRRT). In other studies, 90Y-DOTATOC has been administered through a vein (IV) to target
      somatostatin receptor positive tumor tissue. The DOTATOC identifies the tumor through the
      somatostatin receptor and links to it, attaching the radioactive molecule 90Yttrium to the
      malignant cell.

      This study expands the initial work to examine if administering the drug 90Y-DOTATOC directly
      to the liver is safe for patients with neuroendocrine tumors whose disease has spread to
      their tumor. We don't know how of the 90Y-DOTATOC is safe to administer. We want to learn
      what the maximum safe dose is and what the side effects are related to that dose.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 11, 2018</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2025</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>This is a sequential early phase 1 study using Storer's phase 1 design B.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in liver enzymes</measure>
    <time_frame>Through 6 weeks after treatment</time_frame>
    <description>Evaluate liver toxicity using the Common Terminology Criteria for Adverse Events (CTCAE) severity scale for liver enzymes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in platelet counts</measure>
    <time_frame>Through 6 weeks after treatment</time_frame>
    <description>Evaluate bone marrow toxicity using the Common Terminology Criteria for Adverse Events (CTCAE) severity scale for platelet count</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in absolute neutrophil count</measure>
    <time_frame>Through 6 weeks after treatment</time_frame>
    <description>Evaluate bone marrow toxicity using using the Common Terminology Criteria for Adverse Events (CTCAE) severity scale for absolute neutrophil count</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>90Y-DOTATOC distribution</measure>
    <time_frame>48h post-infusion</time_frame>
    <description>Determine the distribution of 90Y-DOTATOC using post-treatment imaging</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Neuroendocrine Tumors</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject will be administered 2.96 gigabecquerels of [90]Y-DOTATOC intra-aterially to the liver</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject will be administered 3.33 gigabecquerels of [90]Y-DOTATOC intra-aterially to the liver</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject will be administered 3.7 gigabecquerels of [90]Y-DOTATOC intra-aterially to the liver</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject will be administered 4.17 gigabecquerels of [90]Y-DOTATOC intra-aterially to the liver</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject will be administered 4.44 gigabecquerels of [90]Y-DOTATOC intra-aterially to the liver</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject will be administered 5.18 gigabecquerels of [90]Y-DOTATOC intra-aterially to the liver</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[90]Y-DOTATOC</intervention_name>
    <description>Intra-arterial infusion to the liver of [90]Y-DOTATOC. The administered dose is determined by cohort and is dependent upon the results of the previous cohort.</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_label>Cohort 6</arm_group_label>
    <other_name>90Y-DOTATOC</other_name>
    <other_name>90Y-DOTA-Phe1-tyr3-Octreotide</other_name>
    <other_name>[90]Yttrium-DOTATOC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ability to understand and the willingness to provide informed consent

          -  Pathologically well-differentiated neuroendocrine tumor (i.e. grade 1 or grade 2).

          -  Primary tumor location should be known or believed to be midgut.

          -  At least one tumor in the liver that is positive with [68]Ga-DOTATATE (NETSPOT).
             Imaging must be performed within the past 6 months.

          -  Liver lesions not amendable to other therapies (surgery, ablation) and have progressed
             after treatment with octreotide/lanreotide and/or other treatments. (everolimus,
             sunitinib).

          -  Karnofsky performance status of at least 70

          -  Absolute neutrophil count of at least 1,000 cells/mm3

          -  Platelet count of at least 90,000 cells / mm3

          -  Total bilirubin ≤ 2 x the upper limit of normal when adjusted for age

          -  AST and ALT ≤ 5 x the upper limit of normal when adjusted for age

          -  Serum creatinine ≤ 1.2 mg/dl; if serum creatinine is &gt;1.2 mg/dl nuclear GFR will used
             for potentially eligible participants.

          -  Agrees to contraception.

        Exclusion criteria:

          -  Liver tumor involvement greater than 70% by cross sectional imaging

          -  Extra-hepatic visceral and osseous metastases

          -  Concomitant therapy for tumor (except for somatostatin analogs or bisphosphonates)

          -  Previous PRRT or other liver directed therapy within 12 months of consent

          -  Women who are pregnant, breast feeding or breast pumping.

          -  Another concurrent malignancy on active therapy

          -  Previous external-beam radiation therapy to a kidney (including scatter dose)

          -  Therapeutic investigational drug within 4 weeks of therapy.

          -  Subjects for whom, in the opinion of their physician, a 24-hour discontinuation of
             somatostatin analogue therapy represents a health risk.

          -  Sandostatin LAR injection within 4 weeks or lanreotide injection within 8 weeks of
             proposed therapy.

          -  Inability to lie down supine for study procedure.

          -  Reaction to IV contrast used for the angiogram.

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection requiring hospitalization, symptomatic congestive heart failure, unstable
             angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that
             would limit compliance with study requirements
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>M. S O'Dorisio, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Iowa</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sandeep Laroia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Iowa</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sandeep Laroia, MD</last_name>
    <phone>(319) 356-3859</phone>
    <email>sandeep-laroia@uiowa.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yusuf Menda, MD</last_name>
    <phone>(319) 356-3214</phone>
    <email>yusuf-menda@uiowa.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Holden Comprehensive Cancer Center</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristin Gaimari-Varner, RN, BSN</last_name>
      <phone>319-384-5489</phone>
      <email>kristin-gaimari-varner@uiowa.edu</email>
    </contact>
    <contact_backup>
      <last_name>Veronica Howsare</last_name>
      <phone>(319) 384-6469</phone>
      <email>veronica-howsare@uiowa.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Kennedy A, Bester L, Salem R, Sharma RA, Parks RW, Ruszniewski P; NET-Liver-Metastases Consensus Conference. Role of hepatic intra-arterial therapies in metastatic neuroendocrine tumours (NET): guidelines from the NET-Liver-Metastases Consensus Conference. HPB (Oxford). 2015 Jan;17(1):29-37. doi: 10.1111/hpb.12326. Epub 2014 Sep 4. Review.</citation>
    <PMID>25186181</PMID>
  </reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>October 25, 2018</study_first_submitted>
  <study_first_submitted_qc>October 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 30, 2018</study_first_posted>
  <last_update_submitted>September 5, 2019</last_update_submitted>
  <last_update_submitted_qc>September 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Iowa</investigator_affiliation>
    <investigator_full_name>Sandeep Laroia</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>PRRT</keyword>
  <keyword>Radionuclide</keyword>
  <keyword>DOTATOC</keyword>
  <keyword>intra-arterial</keyword>
  <keyword>peptide receptor radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroendocrine Tumors</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Octreotide</mesh_term>
    <mesh_term>Edotreotide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data will be shared as per approved IRB application and the subject's opt-in preferences. Data will not be provided from subjects who decline data sharing.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>Considered upon request.</ipd_time_frame>
    <ipd_access_criteria>Contact study PI regarding data sharing. A non-disclosure agreement may be required between institutions dependent upon the data requested.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

